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Background: A field trial was carried out with two Mycoplasma hyopneumoniae vaccines in order to investigate the
benefit of vaccination under field conditions in modern Danish pig production facilities with pigs being positive for
M. hyopneumoniae. The M. hyopneumoniae infection of the herd was confirmed through blood samples that were
positive for antibodies against M. hyopneumoniae combined with gross lesions of the lungs related to M.
hyopneumoniae at slaughter and detection of M. hyopneumoniae by polymerace chain reaction in these lesions.
Results: A total of 2,256 pigs from two herds were randomly divided into three groups. Group 1 received 2 mL
ThoroVAX®VET, Group 2 received 1 mL Ingelvac®MycoFLEX, and Group 3 was a non-vaccinated control group. The
vaccination was performed by a person who was not involved in the rest of the trial and vaccination status thereby
blinded to the evaluators.
The prevalence of lung lesions related to M. hyopneumoniae were significantly lower for pigs vaccinated with
ThoroVAX®VET but not for pigs vaccinated with Ingelvac®MycoFLEX®, when compared to non-vaccinated pigs. There
was no significant effect of vaccination on growth rate, antibiotic consumption or mortality.
Conclusion: This trial demonstrated that vaccination with Thoro®VAX VET was effective in reducing the prevalence
of lung lesion in pig units infected with M. hyopneumoniae.
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Swine enzootic pneumonia causes major economic losses
in the pig industry worldwide [1]. Mycoplasma hyopneu-
moniae is the primary agent responsible, although second-
ary infections can increase the severity of the disease [2,3].
This interaction with both bacterial and viral pathogens is
referred to as porcine respiratory disease complex [4].
Therefore, control of M. hyopneumoniae is critical in re-
ducing economic losses in the pig industry.
Active immunisation of pigs has been recommended
for preventing M. hyopneumoniae disease and reduced
productivity. A meta-analysis of the effect of M. hyop-
neumoniae vaccines showed an increase in the average
daily gain (ADG) of 20 g for vaccinated finishers com-
pared with non-vaccinated pigs [5].
Pig production levels in Denmark are very high; the
ADG from a body weight of 30–100 kg is 905 g and the
mortality is 3.6% [6]. This high level of productivity is* Correspondence: Charlotte S Kristensen csk@lf.dk
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article, unless otherwise stated.mainly due to modern production units operated on an
all-in/all-out basis and with a high level of biosecurity.
Due to the widespread occurrence of M. hyopneumo-
niae, a large number of pigs are vaccinated against M.
hyopneumoniae. Annually, more than 11 million doses
of vaccine againstM. hyopneumoniae are sold in Denmark
for the production of 30 million pigs, of which nine mil-
lion nursery pigs are exported, and 21 million pigs are
slaughtered in Denmark.
It could be questioned whether the benefit of vaccination
is still valid in modern pig production systems with a high
level of biosecurity, which are becoming more and more
widely adopted worldwide. Therefore, the aim of this study
was to evaluate the effect of two vaccines against M. hyop-
neumoniae on the prevalence of lung lesions, ADG, anti-
biotic consumption and mortality in such facilities.
Methods
Selection of herds
Two herds were selected for this trial on the basis of a
history of clinical respiratory problems.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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It was a specific pathogen free (SPF) herd but infected
with M. hyopneumoniae, Porcine reproductive and re-
spiratory syndrome virus (PRRS) types 1 and 2 and hous-
ing only nursery and grower/finisher pigs. The herd
received 575 four-week-old piglets every 4th weeks, which
were assigned to two sections. The two sections of nursery
pigs were commingled in one grower/finisher section.
Both nursery and grower/finisher units were operated on
an all-in/all-out basis by section. The pigs were treated for
oedema disease with antibiotics during the first three
weeks after arrival. Before inclusion in the trial, lung lesion
scores were evaluated in 30 pigs from one delivery batch
as described by [2]. This evaluation found that 87% of the
pigs had catarrhal bronchopneumonia. M. hyopneumoniae
was detected by an in-house polymerase chain reaction
(PCR) assay at the Danish Veterinary Institute (Copenhagen,
Denmark) from one lung with catarrhal bronchopneumonia,
and antibodies against M. hyopneumoniae were detected by
enzyme-linked immunosorbent assay (ELISA) at the Danish
Veterinary Institute in ten out of ten finishers [7].
Herd B was located in the middle of Jutland. It was a
SPF herd infected with M. hyopneumoniae and Actino-
bacillus pleuropneumonia serotypes 6 and 12. The herd
was a farrow-to-finish production unit consisting of 380
sows producing between 300 and 500 pigs every second
week. At weaning, at four weeks of age, the pigs were
moved to a section that was operated on an all-in/all-out
basis. The grower/finisher units were mainly operated on
an all-in/all-out basis by section. Before inclusion in the
trial, lung lesion scores were evaluated in 30 pigs from
one delivery batch as described by [2]. This evaluation
found that 60% of the pigs had catarrhal bronchopneumo-
nia. M. hyopneumoniae and antibodies were detected as
for herd 1.
Before inclusion the herd owners had to sign informed
client consent.
Vaccines
The vaccines tested in this study were marketed as
ThoroVAX®VET (M+ PAC outside Denmark; MSD Ani-
mal Health, Ballerup, Denmark) and Ingelvac®MycoFLEX
(Boheringer Ingelheim Animal Health, Copenhagen,
Denmark). Both vaccines contain inactivated M. hyop-
neumoniae. ThoroVAX®VET has an aluminium hydroxide
and oil emulsion adjuvant, and Ingelvac®MycoFLEX has a
Carbomer adjuvant. Both vaccines were used according to
their Summary of Product Characteristics (SPC’s).
Experimental design
Pigs were included in the trial just after weaning at four
weeks of age and were given ear tags with an individual
number in the same colour. The pigs were randomly
assigned to one of three treatment groups according to arandomisation list prepared beforehand. Pigs in group 1
were injected intramuscularly (im) in the neck once with
2 mL of ThoroVAX®VET. Pigs in group 2 were injected
im once with 1 mL of Ingelvac®MycoFLEX. Pigs in group
3 were included as non-vaccinated controls. The vaccin-
ation was performed by a person who was not involved in
other parts of the trial and vaccination status was thereby
blinded to the evaluators. The pigs from all three groups
were commingled within the pens. All the pigs within an
age group were included, with 1/3 left non-vaccinated and
2/3 vaccinated against M. hyopneumoniae.
In herd A, pigs were included at two different times
(two batches), and in herd B pigs were included at three
different times (three batches).
The study was approved by the Danish Health and Medi-
cines Authority (www.sundhedsstyrelsen.dk; J.no. 2011081993).
Data recordings
Clinical observations
The pigs were observed daily for reactions to the vaccin-
ation, for clinical signs of disease and abnormalities.
Growth rate
In order to assess ADG, all pigs were weighed individu-
ally at three different times: on the day of inclusion in
the trial, when the batch was moved from the nursery to
the grower/finisher unit and when the first pig in the
batch was ready for slaughter.
Antibiotic use
Individual antibiotic treatment of the pigs included in the
trial was recorded daily by the farmer, who also recorded
whether or not the treatment was due to respiratory
symptoms. Antibiotic treatment frequency was calculated
for nursery and grower/finisher pigs in each treatment
group.
Mortality
All pigs that died during the study were recorded.
Pathology
A subset of dead pigs was necropsied to validate the
cause of death at the Laboratory for Swine Diseases,
Kjellerup, Denmark. A gross pathological examination
was performed.
Pigs were slaughtered when they reached market weight
(110 kg). At the abattoir, the lung from each pig was col-
lected and marked with the treatment group number. At
the Laboratory for Swine Diseases, Kjellerup, Denmark the
lung lesions were evaluated as described by Christensen
et al. [2]. Briefly, each lung was scored yes/no with regard
to presence of uncomplicated catarrhal bronchopneumonia
(presumable caused only by M. hyopneumoniae), compli-
cated catarrhal bronchopneumonia (presumable aggravated
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viously affected with catarrhal bronchopneumonia). From
this, the number of pigs with at least one M. hyopneumo-
niae-like lesion (lungs with uncomplicated catarrhal bron-
chopneumonia, complicated catarrhal bronchopneumonia
or fissures) was calculated. Besides this, the volume per-
centage of lung tissue affected by uncomplicated or compli-
cated catarrhal bronchopneumonia was roughly estimated
[See Figure 1 for examples].Statistical analysis
The sample size was based on lung lesions and ADG.
With regard to lung lesions, expressed as a percentage
of lungs with no lesions at all, it was assumed that a dif-
ference of 13 percentage points between groups in the
range of 40% - 60% could be found. With a level of con-
fidence of 95% and a power of 80%, the sample size was
206 animals per vaccination group per herd. With regard
to ADG, it was assumed that a difference of 30 g per day
between groups in the range of ADG of 900 g per day
and an assumed variation of 120 g per day could be
found. With a level of confidence of 95% and a power of
80%, the sample size was 253 animals per group per
herd.Figure 1 Example of how the individual lung lobs contributed
to the calculation of the total lung volume.To allow both parameters to be evaluated in the trial,
it was necessary to select 250 test animals per group per
herd. In order to allow for mortality, lost ear tags and
missing pigs, the calculated number were increased by
20% based on previous experiences. Thus, the sample
size was 300 pigs per treatment group in each herd.
The prevalence of lungs with 1) uncomplicated catarrhal
bronchopneumonia, 2) complicated catarrhal broncho-
pneumonia, 3) fissures and 4) at least one M. hyopneumo-
niae-like lesion for each treatment group and each herd
was calculated. Four separate logistic regression analyses
were performed for each of the four lung lesion preva-
lences. Mortality was also analysed by a logistic regression.
The percentage of the total lung volume with uncom-
plicated catarrhal bronchopneumonia and complicated
catarrhal bronchopneumonia lesions, ADG and anti-
biotic treatment frequency were used as an outcome in
three separate linear regressions. ADG and antibiotic
treatment were compared for nursery and grower/fin-
isher pigs separately. The start weight was included as a
fixed effect in models with ADG.
PROC GENMOD from the statistical package SAS®
was used for logistic regression, and PROC MIXED was
used for linear regression (SAS Inst. Inc., Cary, NC).
Herd, treatment group and gender were included as
fixed effects in all models. To test for different results in
the herds, an interaction with herd and treatment group
was included. A significance level of 5% was used.
Results
Although only 900 pigs per herd were needed, a total of
2,256 pigs were included in the field trial. The distribu-
tion between herd and treatment group can be seen in
Table 1.
In herd B, one pig (vaccinated with Ingelvac®Myco-
FLEX) was missing at the end of the nursery period. At
weighing before slaughter, two pigs (vaccinated with Ingel-
vac®MycoFLEX ) from herd A and 11 pigs ( four control,
two vaccinated with ThoroVAX®VET and five vaccinated
with Ingelvac®MycoFLEX group) from herd B were miss-
ing. A total of only 14 pigs out of 2,256 were missing be-
fore the final weighing in the two herds.
Clinical observations
No adverse reactions were observed in any of the pigs
following vaccination.
Growth rate
In this trial, the mean weights at inclusion were equal in
the three treatment groups in both herds (Table 2). No
statistically significant differences for ADG were shown
between the vaccinated groups and the control groups
in the nursery period (P = 0.29) and grower/finisher
period (P = 0.84) (Table 2).
Table 1 Distribution of pigs in a field trial of vaccines against M. hyopneumoniae
Herd A B
Treatment group ThoroVAX®VET Ingelvac®MycoFLEX Control ThoroVAX®VET Ingelvac®MycoFLEX Control
Number of pigs 379 377 393 368 363 376
Total number of pigs 1149 1107
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In herd A, all pigs were batch medicated to avoid
oedema disease for the first three weeks after entry into
the nursery unit. Besides this, no batch medication was
used in the two herds. A few pigs were treated for re-
spiratory symptoms. In herd B, three nursery pigs (one
control pig and two ThoroVAX®VET-vaccinated pigs)
and six grower/finisher pigs (three ThoroVAX®VET-
vaccinated pigs and three Ingelvac®MycoFLEX-vaccinated
pigs) were treated. In herd A, no individual treatment was
given due to respiratory symptoms.
In herd A, individual treatment was given to 1.0% -
3.4% of the nursery pigs. In herd B, 1.4% - 3.3% of the
nursery pigs were treated with antibiotics. In the grower/
finisher period, 0.8% - 2.0% of the pigs in herd A were
treated with antibiotics, and in herd B 5.2% - 6.1% of the
pigs were treated (Table 2). There were no statistically sig-
nificant differences in the percentage of pigs treated with
antibiotics for nursery pigs (P = 0.54) and grower/finisher
pigs (P = 0.38) in the two herds.
Mortality
The mortality for nursery pigs in herd A was between
2.9% and 3.2% and in herd B between 1.3% and 1.9% in
the treatment groups (Table 2). The higher mortality in
herd A was mainly due to oedema disease. For grower/
finishers, the mortality in herd A was between 3.2% and
3.6% and for herd B between 2.3% and 3.6% in theTable 2 The effect of vaccinations on growth performance, an
Herd A
Treatment group ThoroVAX®VET Ingelvac®My
Nursery pigs
Mean weight start nursery (sd*) 7.2 (1.3) 7.3 (1.2)
Mean weight end nursery (sd) 32.7 (7.5) 32.8 (7.6)
ADG** nursery (sd) 508 (9) 516 (9)
Pigs individually treated with antibiotics (%) 1.9 3.4
Mortality (%) 2.9 3.2
Grower/finishers
Mean weight when first pig in a batch was
ready for slaughter (sd)
79.4 (14.6) 79.4 (14.4)
ADG grower/finisher pigs (sd) 868 (11) 863 (11)
Pigs individually treated with antibiotics (%) 1.9 0.8
Mortality (%) 3.5 3.6
*Sd: Standard deviation of the mean. **ADG: Average daily gain.treatment groups (Table 2). No statistically significant
differences between the treatment groups were observed
for nursery pigs (P = 0.90) or grower/finishers (P = 0.73).
From herd A, 13 pigs (six control, four vaccinated
with ThoroVAX®VET and three vaccinated with Ingel-
vac®MycoFLEX) were necropsied, and for herd B six
pigs (two control, three vaccinated with ThoroVAX®-
VET and one vaccinated with Ingelvac®MycoFLEX) were
necropsied. The unequal distribution of necropsied pigs
was due to the blinding, which made it impossible to
know which treatment the pig had received. None of the
necropsied pigs (n = 19) died due to respiratory diseases.
Pathological findings
A total of 1,831 lungs were collected at the abattoir
(867 from herd A and 964 from herd B). A further 176
lungs from herd A and 65 lungs from herd B were lost
due to technical reasons, with an equal distribution be-
tween the three treatment groups for these missing
lungs.
The prevalence of pigs with at least one M. hyopneu-
moniae-like lung lesion in each treatment group, at each
delivery date, can be seen in Figure 2. Fluctuations in
the prevalence of pigs with at least one M. hyopneumo-
niae-like lung lesion were seen over time.
The interaction between herd and treatment group was
statistically significant in the models with uncomplicated
catarrhal bronchopneumonia, number of lungs with attibiotic treatment and mortality
B
coFLEX Control ThoroVAX®VET Ingelvac®MycoFLEX Control
7.2 (1.2) 6.5 (1.8) 6.5 (1.8) 6.5 (1.6)
32.5 (7.4) 31.6 (6.1) 32.4 (5.9) 31.4 (5.4)
507 (9) 538 (10) 545 (10) 537 (10)
1.0 3.3 1.4 3.2
3.1 1.9 1.9 1.3
79.1 (15.3) 76.3 (11.6) 76.9 (11.4) 75.5 (11.8)
867 (11) 807 (11) 803 (11) 807 (11)
2.0 5.2 5.5 6.1
3.2 3.6 2.3 2.7
Figure 2 Prevalence of pigs with at least one Mycoplasma hyopneumoniae-like lung lesion in each treatment group, at each delivery date.
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to different levels of lung lesions within the herds. There-
fore, the results from these models are reported for each
herd individually.
Statistically significantly fewer pigs vaccinated with
ThoroVAX®Vet had uncomplicated catarrhal broncho-
pneumonia compared with the control group of non-
vaccinated pigs (Herd A: P =0.05; Herd B: P < 0.0001).
There were no statistically significant differences between
pigs vaccinated with Ingelvac®MycoFLEX compared with
the control group of non-vaccinated pigs for uncompli-
cated catarrhal bronchopneumonia (Herd A: P = 0.97;
Herd B: P = 0.29) (Table 3).Table 3 The prevalence of lung lesions and mean percentage
complicated catarrhal pneumonia lesions (volume %) at slaug
Herd A
Treatment group ThoroVAX®VET Ingelvac®M
N* lungs obtained 285 283
N uncomplicated catarrhal pneumonia (%) 130b 152a
(45.6) (53.7)
N complicated catarrhal pneumonia (%) 0 2
(0) (0.7)
N fissures (%) 53a (18.6) 53a (18.7)
N of pigs with at least one M. hyopneumoniae
like lung lesion (%)
156b (54.7) 171a (60.4)
Volume (%) (sd)*** 9.0b 10.7a
(7.1) (8.4)
*N: Number. **a/b indicated significant (P <0.05) difference from the reference grouThe prevalence of pigs with complicated catarrhal
bronchopneumonia was very low, and therefore no stat-
istical analysis was performed for complicated catarrhal
bronchopneumonia (Table 3).
Statistically significantly fewer pigs vaccinated with
ThoroVAX®Vet had at least one M. hyopneumoniae-like
lung lesion compared with the control group of non-
vaccinated pigs (Herd A: P = 0.04; Herd B: P < 0.0001 ).
For Ingelvac®MycoFLEX, no statistically significant dif-
ferences were found when comparing to the control
group (Herd A: P = 0.49; Herd B: P = 0.39) (Table 3).
For fissures, a statistically significant difference was found
when comparing pigs vaccinated with ThoroVAX®Vet withof the total lung volume with uncomplicated and
hter
B
ycoFLEX Control ThoroVAX®VET Ingelvac®MycoFLEX Control
299 324 306 334
161a** 51b 104a 127a (38.0)
*(53.9) (15.7) (34.0)
4 1 8 1
(1.3) (0.3) (2.6) (0.3)
50a (16.7) 63b (19.4) 86a (28.1) 104a (31.1)
189a (63.2) 105b (32.4) 159a ( 52.0) 185a (55.4)
11.9a 6.3b 8.6a 9.0a
(9.1) (4.4) (6.7) (7.6)
p “Control”. ***Sd: standard deviation of the mean.
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(P = 0.55). When comparing the Ingelvac®MycoFLEX-
vaccinated pigs with the control group, no statistically
significant differences were found (Herd A: P = 0.52;
Herd B: P = 0.40).
The percentage of the total lung volume with uncom-
plicated and complicated catarrhal bronchopneumonia
was statistically significantly lower for ThoroVAX®Vet-
vaccinated pigs compared with the control group of
non-vaccinated pigs (P = 0.001). There were no statisti-
cally significant differences between pigs vaccinated with
Ingelvac®MycoFLEX compared with the control group of
non-vaccinated pigs when comparing the percentage of
the total lung volume with uncomplicated and compli-
cated catarrhal bronchopneumonia (P = 0.16) (Table 3).
Discussion
The prevalence of lung lesions related to M. hyopneumo-
niae was statistically significantly reduced for pigs vacci-
nated with ThoroVAX®VET but not for pigs vaccinated
with Ingelvac®MycoFLEX compared with a non-vaccinated
control group in two modern Danish pig production sites
with a high level of biosecurity. There was no statistically
significant effect of vaccination on growth rate, antibiotic
consumption and mortality. It was surprising that no
difference was found between lung lesions and ADG,
since this correlation has been observed in several
studies e.g. [8-10], although missing in another [11].
The lack of correlation between lung lesions and
growth rate, together with the low ADG seen in the
study, could be explained by the fact that a batch of
pigs was weighed when the first pig within the batch
reached slaughter weight. At that time, the average
weight was 75–80 kg, with a normal slaughter weight
of 100–110 kg, and therefore some pigs had to remain
in the grower/finishing unit for a further seven to eight
weeks before being sent for slaughter. Furthermore, it
was decided not to put restrictions on the normal de-
livery strategy for the herds, forcing the farmer to de-
liver pigs before they had reached slaughter weight. If
the infection with M. hyopneumoniae was late, which
the large number of pigs with catarrhal bronchopneu-
monia indicates, the ADG would be most reduced late
in the grower/finishing phase. In this phase, pigs vacci-
nated with ThoroVAX®VET seemed to be best pro-
tected, since they had the lowest prevalence of lung
lesions. Therefore, it could be hypothesised that the
ThoroVAX®VET-vaccinated pigs would have a higher
ADG, compared with the control, if all of the pigs had
been weighed just before slaughter.
Overall, no benefit of vaccination was found in anti-
biotic treatment. A few vaccinated pigs were treated for
respiratory diseases. The daily treatment was given by
the farmer, and, despite careful training of the farmer inclinical observation, it could be questioned whether the
observations were made correctly.
This trial was conducted in modern facilities with high
performance and a good level of biosecurity. Neverthe-
less, ThoroVAX®VET was found to reduce the preva-
lence of lung lesions related to M. hyopneumoniae
significantly. The best effect of vaccination was found in
Herd B, although a good effect was also found in herd
A. It is important to note that there were fluctuations in
the prevalence of lung lesions related to M. hyopneumo-
niae over time for both herds. At one point, even the
control non-vaccinated pigs had the lowest prevalence of
lung lesions related to M. hyopneumoniae. The diverging
effects in efficacy between herds and over time emphasize
the complexity of the porcine respiratory disease complex.
Therefore, it is important not only to make one evaluation
of lung lesions when investigating the reason for a respira-
tory problem within a herd. It should always be supple-
mented with detection of the agent/agents and/or blood
samples etc.
The effect of both vaccines might be underestimated
in this study, since only parts of the total populations
were vaccinated. This might lead to a lower level of pro-
tection at herd level, and, if non-immune pigs develop
disease, they will increase the general pathogen load -
not only associated with M. hyopneumoniae but the por-
cine respiratory disease complex in general. Therefore,
vaccination against M. hyopneumoniae might still be an
economic benefit in modern pig production with a high
level of biosecurity despite the lack of increased ADG in
this study.
Conclusion
The prevalence of lung lesions related to M. hyopneumo-
niae were statistically significantly reduced for pigs vac-
cinated with ThoroVAX®VET but not for pigs vaccinated
with Ingelvac®MycoFLEX® compared with a non-vaccinated
control group.
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